VXDS

Takeda will study the type 2 diabetes drug Actos as an Alzheimer's prevention treatment with the help of Zinfandel Pharmaceuticals' TOMM40 test to gauge which older adults at high risk of disease onset should be enrolled in clinical trials.

Zineh recently answered PGx Reporter's questions about the agency's efforts in pharmacogenomics and personalized medicine.

Ariana Pharma announced this week that the FDA will use its KEM Biomarker technology to "systematically identify potential genomic 'fingerprints' and develop recommendations for the analysis of genomic data prior to submission of biomarker signatures."

Studies presented at an international conference this week suggest that TOMM40 genotyping could be a useful diagnostic strategy for predicting which healthy people with a family history of Alzheimer's will develop the disease early.

In a recent issue of The Pharmacogenomics Journal, a team led by Allen Roses, director of Duke University's Deane Drug Discovery Institute, published data from two independent study populations linking longer lengths of a polymorphic poly-T variant, rs10524523, with a higher risk of late-onset Alzheimer's disease. "This paper provides the data and the first opportunity for other research laboratories to test and validate the data," the study authors note.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.